Q2 2026 Globus Medical, Inc. Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €68.92 (-1.63%)

Transcript 10-Q8-K

Key Points

Positve

Globus Medical Inc (GMED) delivered exceptional Q2 2026 results with revenue of $789.6 million, growing 6% as reported, and 9% growth in the base business excluding Nevro.
The company achieved a record quarterly non-GAAP EPS of $1.34, growing 56% year-over-year, and adjusted EBITDA margin expanded 740 basis points to 35.4%.
US Spine continued its strong performance with 7% growth, marking the fifth consecutive quarter of above-market growth, driven by competitive recruiting and product launches.
International Spine grew 14% as reported, with double-digit growth across key EMEA markets, APAC, and LATAM, reflecting successful market penetration strategies.
The company raised its full-year 2026 non-GAAP EPS guidance to $4.95-$5.05, up from $4.70-$4.80, reflecting strong margin expansion and operating leverage.

Negative

Nevro sales declined 14.3% year-over-year and saw a sequential decline of $1.7 million, with the company expecting trial volume recovery only by late Q4 2026.
Enabling Technologies revenue declined 26% in Q2, driven by a strategic shift towards more flexible capital acquisition models, which creates near-term revenue pressure.
US Spine growth slowed to 7% from the prior 10% rate, with management noting more difficult year-over-year comparisons in the second half of 2026.
The company chose not to raise its full-year revenue guidance despite the Q2 beat, citing caution around the enabling tech strategy shift and Nevro's stabilization.
R&D expenses are expected to ramp significantly in the back half of 2026 to reach the 5%-6% of sales target, potentially impacting near-term profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GMED.N - Globus Medical, Inc.
Q2 2026 Globus Medical, Inc. Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Globus Medical's second quarter 2026 earnings call. At this time, all lines will be on mute, and a Q&A session will be held after the prepared remarks.

I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Sarah, and thank you everyone for being with us today.

Joining today's call from Globus Medical will be Keith File, President and Chief Executive Officer, and Kyle Klein, Chief Financial Officer.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.